While the development of BCR-ABL-targeted tyrosine kinase inhibitors (TKIs) has revolutionized CML treatment, researchers have attempted to develop PROTACs capable of inducing the degradation of the BCR-ABL fusion protein. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.